FDA approves drug to treat neurologic manifestations of Hunter syndrome

Key Points

• This research addresses the treatment of neurologic manifestations associated with Hunter syndrome.
• FDA approval for Avlayah as a treatment option.
• Focus on neurologic symptoms related to Hunter syndrome.
• Avlayah is approved for specific individuals with Hunter syndrome.
• The approval signifies a new therapeutic approach for managing neurologic manifestations.